On 17 August 2026, an analysis was published in Diabetes, Obesity & Metabolism that is not about weight, but about what happens in the blood. Researchers retrospectively analysed data from two randomised, double-blind, placebo-controlled phase 2 trials. In the first, adults with type 2 diabetes were followed for 36 weeks. In the second, adults with clinical obesity without diabetes were followed for 48 weeks. Mean body mass index was 35,4 and 37,4, respectively. Retatrutide is a triple agonist: it acts simultaneously at two gut-hormone receptors and the glucagon receptor. Most discussions around it focus on metabolism. This analysis looked elsewhere — at lipoproteins and inflammatory markers associated with cardiovascular risk.
What they recorded
In the particle measurements, the changes were large. Large triglyceride-rich particles decreased by up to 84,4% in one trial and 76,6% in the other. The cholesterol in these particles decreased by 29,4% and 38,6%. Among conventional markers, non-HDL cholesterol decreased by up to 21,0% and 26,9%, while apolipoprotein B — which measures the number of atherogenic particles and is considered by many to be a more reliable marker than cholesterol — decreased by 21,4% and 24,2%. Small LDL particles, which are particularly associated with atherosclerosis, decreased by approximately 32% in both trials. For inflammation, the findings were asymmetrical. In the trial without diabetes, high-sensitivity C-reactive protein decreased by 54,8% and interleukin-6 by 29,6%. In the trial with diabetes, the same changes did not reach statistical significance.
What this study does not show
Caution is needed here, because the distinction is substantial. This is a post-hoc analysis: the researchers examined data that had already been collected, for a question that was not the original objective of the trials. Such analyses generate hypotheses; they do not confirm them. Second, biomarkers were measured, not outcomes. Neither trial was designed to show whether heart attacks or strokes are reduced. A marker moving in the “right” direction does not automatically mean fewer cardiovascular events — medicine has many examples where this was not the case. Third, this is phase 2. The number of participants is limited and the follow-up period is short for conclusions about cardiovascular safety. Fourth, the discrepancy in inflammatory markers between the two trials remains unanswered.
Why it matters
Research around triple molecules is at an early stage and the studies are small. What makes this particular analysis noteworthy is not the size of the percentages, but that it shifts attention from metabolism to the vascular profile — a question that can only be settled by large phase 3 trials with actual outcomes. Related analysis: what products contain.
Sources
Ruotolo G. et al., Diabetes, Obesity & Metabolism, 17 August 2026. DOI: 10.1111/dom.71200 — https://doi.org/10.1111/dom.71200 ClinicalTrials.gov protocols: NCT04881760 and NCT04867785. Retrieved via PubMed. Retatrutide has not been approved by the FDA or EMA. It remains at the research stage. Products are supplied exclusively for research use.